Literature DB >> 19648603

Sorafenib and sunitinib.

AeRang Kim1, Frank M Balis, Brigitte C Widemann.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19648603      PMCID: PMC6626665          DOI: 10.1634/theoncologist.2009-0088

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  21 in total

1.  Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.

Authors:  Rana R McKay; Gustavo E Rodriguez; Xun Lin; Marina D Kaymakcalan; Ole-Petter R Hamnvik; Venkata S Sabbisetti; Rupal S Bhatt; Ronit Simantov; Toni K Choueiri
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Tatiana M Fontelonga; Brennan Jordan; Andreia M Nunes; Pamela Barraza-Flores; Nicholas Bolden; Ryan D Wuebbles; Lesley Mathews Griner; Xin Hu; Marc Ferrer; Juan Marugan; Noel Southall; Dean J Burkin
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

3.  Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification.

Authors:  Dan L Li; Zhao V Wang; Guanqiao Ding; Wei Tan; Xiang Luo; Alfredo Criollo; Min Xie; Nan Jiang; Herman May; Viktoriia Kyrychenko; Jay W Schneider; Thomas G Gillette; Joseph A Hill
Journal:  Circulation       Date:  2016-03-16       Impact factor: 29.690

Review 4.  Improving the outcome for children with cancer: Development of targeted new agents.

Authors:  Peter C Adamson
Journal:  CA Cancer J Clin       Date:  2015-03-09       Impact factor: 508.702

5.  Sunitinib tissue distribution changes after coadministration with ketoconazole in mice.

Authors:  Evelyn Li-Ching Chee; Adeline Yi Ling Lim; Pilar Modamio; Cecilia Fernandez-Lastra; Ignacio Segarra
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-06       Impact factor: 2.441

6.  Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs.

Authors:  Anna A Kiseleva; Vladislav A Korobeynikov; Anna S Nikonova; Peishan Zhang; Petr Makhov; Alexander Y Deneka; Margret B Einarson; Ilya G Serebriiskii; Hanqing Liu; Jeffrey R Peterson; Erica A Golemis
Journal:  Clin Cancer Res       Date:  2019-03-13       Impact factor: 12.531

7.  Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.

Authors:  Cen Xie; Jialan Zhou; Zitao Guo; Xingxing Diao; Zhiwei Gao; Dafang Zhong; Haoyuan Jiang; Lijia Zhang; Xiaoyan Chen
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

8.  Activation of RyR2 by class I kinase inhibitors.

Authors:  A D Chakraborty; L A Gonano; M L Munro; L J Smith; C Thekkedam; V Staudacher; A B Gamble; N Macquaide; A F Dulhunty; P P Jones
Journal:  Br J Pharmacol       Date:  2019-01-30       Impact factor: 8.739

9.  Targeting angiogenesis in childhood sarcomas.

Authors:  Hemant K Bid; Peter J Houghton
Journal:  Sarcoma       Date:  2010-12-09

Review 10.  Targeted Therapy in Biliary Tract Cancers.

Authors:  Amartej Merla; Kenneth G Liu; Lakshmi Rajdev
Journal:  Curr Treat Options Oncol       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.